Rani Therapeutics Holdings Insiders Placed Bullish Bets Worth US$1.31m

Multiple insiders secured a larger position in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism about the company's prospects.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Rani Therapeutics Holdings Insider Transactions Over The Last Year

The Executive Chairman Mir Imran made the biggest insider purchase in the last 12 months. That single transaction was for US$1.3m worth of shares at a price of US$0.60 each. That implies that an insider found the current price of US$0.64 per share to be enticing. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Rani Therapeutics Holdings insiders decided to buy shares at close to current prices.

In the last twelve months insiders purchased 2.15m shares for US$1.3m. But they sold 386.00 shares for US$301. In the last twelve months there was more buying than selling by Rani Therapeutics Holdings insiders. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

View our latest analysis for Rani Therapeutics Holdings

Rani Therapeutics Holdings is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Rani Therapeutics Holdings Insiders Bought Stock Recently

We saw some Rani Therapeutics Holdings insider buying shares in the last three months. Executive Chairman Mir Imran bought US$25k worth of shares in that time. It's great to see that insiders are only buying, not selling. However, in this case the amount invested recently is quite small.

Insider Ownership Of Rani Therapeutics Holdings

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests Rani Therapeutics Holdings insiders own 3.1% of the company, worth about US$2.8m. I generally like to see higher levels of ownership.

So What Do The Rani Therapeutics Holdings Insider Transactions Indicate?

Our data shows a little insider buying, but no selling, in the last three months. The net investment is not enough to encourage us much. However, our analysis of transactions over the last year is heartening. We'd like to see bigger individual holdings. However, we don't see anything to make us think Rani Therapeutics Holdings insiders are doubting the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To help with this, we've discovered 5 warning signs (1 is a bit concerning!) that you ought to be aware of before buying any shares in Rani Therapeutics Holdings.

Of course Rani Therapeutics Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.